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1990 to 1997, to 21 months in the period from 1998 to 2000 
(p = 0.062).  Conclusion: The number of patients who died 
from metastatic breast cancer without receiving any anti-
neoplastic therapy was surprisingly high. The use of newer 
agents and regimens in the treatment of metastatic breast 
cancer was associated with an improved survival over time. 
Chemotherapy is a feasible option also among older pa-
tients.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 There exists a vast amount of published clinical trials 
concerning the systemic therapy of metastatic breast can-
cer [overview in 1–6 ]. Nearly all trials, however, concen-
trate only on the feasibility and impact of defined therapy 
options. They focus on the evaluation and comparison of 
particular antineoplastic agents and drugs, but in doing 
so, can only evaluate particular therapy options in prese-
lected groups of patients in certain situations and at a 
certain point of time. Clinical trials which evaluate pa-
tients’ outcome in regard to specific treatments do not 
usually consider the subsequent therapy course of the 
disease when the study period is finished. However, an 
analysis of the entire course of therapy of patients with 
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 Abstract 
 Objective: To depict a clear and coherent picture of the over-
all course of palliative treatment in an unselected study co-
hort over the course of time.  Methods: We compared thera-
py type and course of 242 women whose distant metastatic 
disease was diagnosed from 1990 to 2006 and who ultimate-
ly died of the disease. We divided the patients into two sub-
groups depending on the year of diagnosis of metastases 
(group A: 1998–2006 vs. group B: 1990–1997).  Results: In 
both subgroups, there were no significant differences in the 
general type of treatment and the number of administered 
therapy lines (no systemic therapy: 12.9 vs.13.7%, p = 0.848; 
endocrine therapy only: 20.4 vs. 25.2%, p = 0.430; chemo-
therapy only: 18.4 vs.16.9%, p = 0.735; sequential combina-
tion regimen including endocrine therapy/chemotherapy/
trastuzumab: 46.9 vs. 44.2%, p = 0.694; median: 2 lines). In 
the cases where chemotherapy was administered, there 
were no differences between the number of lines among 
older and younger patients (median: two lines;  6 70 years vs. 
 ! 70 years: p = 0.269). The median metastatic disease-spe-
cific survival increased from 16 months in the period from 
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metastatic breast cancer shows that these patients receive 
a multitude of therapy lines up until death. These subse-
quent therapies are hardly considered in the analysis of 
trial data. Thus, a weak point of these studies is that their 
ability to describe the overall course of recurrent disease 
is limited.
 The goal of this study was to depict a clear and coher-
ent picture of the overall palliative treatment setting and 
to demonstrate its changes and developments over time. 
We did not simply demonstrate specific treatments (this 
is the domain of clinical trials), but rather complete cours-
es of therapy in an unselected group of patients (this is not 
addressed by clinical trials) and by doing so we wanted to 
demonstrate the truth beyond the clinical trials.
 Patients and Methods 
 The Basel Breast Cancer Data Base is comprised of extensive 
data concerning clinical, histo- and pathomorphologic features 
and treatment characteristics of all patients whose primary inva-
sive breast carcinoma was diagnosed and treated at the Univer-
sity Women’s Hospital Basel (Basel, Switzerland) since 1990. For 
this study, we analyzed the data of 1,187 patients who were ini-
tially diagnosed up to 2006. The patients were followed until 
death or, if they remained alive and disease free, for a maximum 
of 15 years. They were seen for a maximum of 6 months before 
conclusion of the data collection in December 2007. With the ex-
ception of 37 patients (3.1% of the entire study group) who were 
lost to follow-up, we could provide outcome information for all 
other patients. Of these, 301 women already had distant metasta-
ses at initial diagnosis (stage IV; n = 67, 5.6%) or developed metas-
tases in the course of time (n = 234, 19.7%). The data regarding 
the course of palliative therapy and outcome of these patients 
form the basis of this study. From these 301 patients, we could 
obtain information regarding the time of diagnosis of metastatic 
disease and date of death but we did not have complete informa-
tion about the therapy course in the palliative situation for 4 pa-
tients. Thus, these were not considered for further analysis, and 
ultimately 297 patients were included in the study.
 It was the goal of our study to give a general overview regard-
ing the actual administered therapies in the systemic treatment of 
metastatic breast cancer. We compared the therapy course and 
outcome of women whose metastatic disease was diagnosed be-
fore 1998 with those whose distant metastases were diagnosed 
after 1998. In order to create homogeneous study groups, we ana-
lyzed only the 242 patients who ultimately died of their metastat-
ic disease. In other words, we analyzed only completed treatment 
courses. Patients who died of other causes (n = 18) or were still 
alive at the conclusion of the observation period (i.e. whose ther-
apies were presumably still ongoing, n = 37) were excluded. For 
the purpose of our study, we listed the number of therapy lines 
and noted the general type of therapy: (1) no systemic treatment, 
(2) endocrine therapy only, (3) chemotherapy only, (4) trastuzum-
ab only, and (5) combination of the therapy types during the 
course of treatment.
 Any change in the therapy regimen, i.e. the agent or combina-
tion of agents used, was viewed as a new line of treatment. The 
study design and data collection methods were approved by our 
institutional review board.
 Statistical Analysis 
 To predict the survival with distant metastatic disease, we 
used the Kaplan-Meier method. Survival was defined as the in-
terval from the date of diagnosis of distant metastases to the date 
of breast cancer-related death. Non-breast-cancer-related deaths 
were censored in the statistical analyses according to the same 
method used for patients who were alive. In this manner, a meta-
static disease-specific survival (MDSS) was calculated. Statistical 
differences between groups in terms of survival curves were ana-
lyzed using the log rank test. To compare ordinal variables (num-
ber of therapy lines) between the two groups, the nonparametric 
exact Wilcoxon test was performed. Comparisons between nom-
inal parameters were made with the Fisher exact test. p  ! 0.05 was 
considered significant. Statistical analyses were performed with 
R Development Core Team software, version 2.5.0 (Vienna, Aus-
tria).
 Results 
 The clinicopathologic and outcome characteristics of 
the 297 patients with metastatic breast cancer included in 
the study are summarized in  table 1 . The majority of the 
patients died of the disease (n = 242, 81.5%). The median 
follow-up time of patients who were alive was 39 months 
(range: 10–172 months). In 3 patients, we observed an 
 asymptomatic long-term survival of more than 12 years.
 Table 2 lists the general type of treatment in the 242 
patients who died of metastatic breast cancer (i.e. com-
pleted therapy courses). Between patients who were ini-
tially diagnosed with metastatic disease between 1990 
and 1997 and those who were diagnosed from 1998 to 
2006, there was a significant difference regarding age 
(60.3 vs. 64.7 years, p = 0.0219). There were no significant 
differences in the general type of treatment (no systemic 
therapy, p = 0.848; endocrine therapy only, p = 0.430; che-
motherapy only, p = 0.735; combination regimen includ-
ing endocrine therapy and/or chemotherapy and/or 
trastuzumab, p = 0.694). Furthermore, the number of ad-
ministered therapy lines did not differ significantly be-
tween the two groups.
 Table 3 shows the general type of palliative treatment 
received by patients dependent on age at initial diagnosis 
of distant metastasis. Even in the subgroups comprised of 
patients younger than 70 years, approximately 10% of pa-
tients did not receive any antineoplastic palliative treat-
ment ( ^  59 years: 10.8%, 60–69 years: 9.1%). Among old-
er patients ( 6 70 years), the percentage of untreated pa-
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Table 1. Clinicopathologic characteristics of 297 patients with 
distant metastatic breast cancer
Variable Group A Group B
Entire group 191 (100) 106 (100)
Stage IV at initial diagnosis 46 (24.1) 20 (18.9)
DM in the course of time 145 (75.9) 86 (81.1)
Median time from initial diagnosis to
diagnosis of DM (range), months 44.5 (2–166) 25.5 (2–100)
Age at diagnosis of DM
Mean (range), years 64.7 (28–92) 60.3 (37–87)
≤59 years 59 (30.9) 53 (50.0)
60–69 years 53 (27.7) 24 (22.6)
≥70 years 79 (41.4) 29 (27.4)
TNM stage1 at initial diagnosis
I 18 (9.4) 8 (7.6)
II 61 (31.9) 38 (35.8)
III 66 (34.6) 40 (37.7)
Hormonal receptor status
Not known 1 (0.5) 17 (16.0)
ER+/PR+ 101 (52.9) 52 (49.1)
ER+/PR– 38 (19.9) 16 (15.1)
ER–/PR+ 3 (1.6) 2 (1.9)
ER–/PR– 48 (25.1) 19 (17.9)
Grading
G1: well differentiated 4 (2.1) –
G2: moderately differentiated 67 (35.1) 16 (15.1)
G3: poorly differentiated 110 (57.6) 75 (70.8)
Not known/not applicable 10 (5.2) 15 (14.1)
HER-2 neu status
Known 151 (79.1) 20 (18.9)
Positive 36 (23.8) 7 (35.0)
Adjuvant therapy
No therapy 25 (17.2)a 24 (27.9)a
Endocrine therapy 93 (64.1)b 50 (58.1)b
Chemotherapy 66 (45.5)c 19 (22.1)c
Metastatic site at initial time of diagnosis of metastatic disease
Bone metastases only 56 (29.3) 31 (29.2)
Visceral metastases 135 (70.7) 75 (70.8)
Outcome status
Died of metastatic disease 147 (77.0) 95 (89.6)
Died of other causes 10 (5.2) 8 (7.5)
Alive 34 (17.8) 3 (2.8)
Unless otherwise indicated figures represent number with the 
percentage in parentheses. Group A = Distant metastases first di-
agnosed in 1998–2006; group B = distant metastases first diag-
nosed in 1990–1997; DM = distant metastases; ER = estrogen re-
ceptor; PR = progesterone receptor.
a p = 0.0493; b p = 0.4016; c p = 0.0004.
1 AJCC (American Joint Committee on Cancer)/UICC (Inter-
national Union Against Cancer) TNM Classification.
Table 2. Palliative treatment setting of 242 patients who died of 
metastatic breast cancer
Variable Group A Group B
Entire group 147 (100) 95 (100)
No systemic therapy 19 (12.9) 13 (13.7)
Mean age (range), years 72.0 (50–91) 63.0 (44–81)
ET only 30 (20.4) 24 (25.2)
Mean age (range), years 72.7 (53–86) 66.2 (44–87)
1 therapy line 22 (15.0) 19 (20.0)
2 therapy lines 8 (5.4) 4 (4.2)
3 therapy lines – 1 (1.0)
Median number of therapy lines 1 1
CT only 27 (18.4) 16 (16.9)
Mean age (range), years 60.5 (32–84) 57.8 (37–82)
1 therapy line 11 (7.5) 7 (7.4)
2 therapy lines 10 (6.8) 3 (3.2)
3 therapy lines 3 (2.0) 5 (5.3)
4 therapy lines 2 (1.4) 1 (1.0)
5–7 therapy lines 1 (0.7) –
Median number of therapy lines 2 2
Trastuzumab only 2 (1.4) –
Age range, years 53–92 –
Combination regimens 69 (46.9) 42 (44.2)
Combination: CT and ET 48 (32.7) 39 (41.1)
Mean age (range), years 62.8 (39–87) 58.7 (37–82)
2 therapy lines 6 (4.1) 8 (8.4)
3 therapy lines 10 (6.8) 9 (9.5)
4 therapy lines 10 (6.8) 9 (9.5)
5–6 therapy lines 21 (14.3) 11 (11.6)
7–8 therapy lines 1 (0.7) 2 (2.1)
Median number of therapy lines 4 3
Combination: 
CT and trastuzumab 13 (8.8) 1 (1.0)
Mean age (range), years 52.5 (28–80) 70
1 therapy line 1 (0.7) –
2–3 therapy lines 5 (3.4) –
4–5 therapy lines 5 (3.4) 1
6–7 therapy lines 2 (2.0) –
Median number of therapy lines 3.5
Combination: CT and ET
and trastuzumab 8 (5.4) 2 (2.1)
Mean age (range), years 56.6 (37–70) 43.5 (42, 51)
4–6 therapy lines 7 (4.7) 1 (1.0)
9 therapy lines 1 (0.7) –
10 therapy lines – 1 (1.0)
Median number of therapy lines 5.5 8
Unless otherwise indicated figures represent number with the 
percentage in parentheses. Group A = Distant metastases first di-
agnosed in 1998–2006; group B = distant metastases first diagnosed 
in 1990–1997; CT = chemotherapy; ET = endocrine therapy.
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tients increased to 19.3%. Comparison of the oldest group 
of patients with the youngest subgroup ( ^  59 years) re-
vealed that older patients were significantly more often 
treated with endocrine therapy only (36.1 vs. 11.8%, p = 
0.0003) and significantly less often with chemotherapy 
containing combination regimens (30.1 vs. 53.7%, p = 
0.0001). In patients  1 65 years, there was no statistical dif-
ference in the percentage of patients who received chemo-
therapy over the course of time (1990–1997: 48.7% vs. 
1998–2006: 47.0%; p = 1.000).
 In the cases where chemotherapy was given, there 
were no differences between the number of lines admin-
istered among the three age-dependent subgroups (me-
dian: 2 lines), and in particular, there was no difference 
between older and younger patients ( 6 70 vs.  ! 70 years; 
p = 0.269). Only 26% of the patients in the current pallia-
tive setting (i.e. diagnosed with distant metastases after 
1998) received more than three chemotherapy lines ( ta-
ble 4 ).
 The MDSS between the study groups showed a trend 
towards an improved survival time in the patients whose 
metastatic disease was diagnosed after 1998 ( fig.1 ; p = 
0.062). In this group (group A), the 3-year adjusted sur-
vival rate was 38.5% compared to group B (23.8%) in 
which distant metastases were diagnosed between 1990 
and 1997; the 5-year rates were 16.6 and 12.6%, respec-
tively. The median MDSS time increased from 16 months 
in the period from 1990 to 1997, to 21 months in the pe-
riod from 1998 to 2000.
 Discussion 
 The outcome of patients with metastatic breast cancer 
varies considerably depending on host and tumor factors/
characteristics  [2, 3] . The primary goal of palliative treat-
Table 3. Type of palliative therapy among patients of different age 
groups who died of metastatic breast cancer
Entire group 242 (100)
(1) ≤59 years 93 (38.4)
No therapy 10 (10.8)
ET only 11 (11.8)
CT only1 22 (23.7)
Combination: CT and/or ET and/or trastuzumab 50 (53.7)
Median number of CT lines 2
(2) 60–69 years 66 (27.3)
No therapy 6 (9.1)
ET only 13 (19.7)
CT only 11 (16.7)
Combination: CT and/or ET and/or trastuzumab 36 (54.5)
Median number of CT lines 2
(3) ≥70 years 83 (34.3)
No therapy 16 (19.3)
ET only 30 (36.1)
CT only1 12 (14.5)
Combination: CT and/or ET and/or trastuzumab 25 (30.1)
Median number of CT lines 2
Unless otherwise indicated figures represent number with the 
percentage in parentheses. ET = Endocrine therapy; CT = chemo-
therapy.
1 In one case, trastuzumab only.
Table 4. Number of chemotherapy lines received by patients who 
died of metastatic breast cancer in a current palliative setting (di-
agnosis of metastases after 1998)
Total of patients who
received chemotherapy
96 (100)
1 therapy line 26 (27.1)
2 therapy lines 31 (32.3)
3 therapy lines 14 (14.6)
4 therapy lines 14 (14.6)
5 therapy lines 7 (7.3)
6 therapy lines 1 (1.0)
7 therapy lines 3 (3.1)
Figures represent number with the percentage in parentheses.
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 Fig. 1. MDSS among 297 patients with distant metastatic breast 
cancer. Group A = Distant metastases first diagnosed in 1998–
2006; group B = distant metastases first diagnosed in 1990–
1997. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 9
:0
0:
39
 A
M
 Systemic Therapy of Metastatic Breast 
Cancer 
Oncology 2009;76:247–253 251
ment includes prevention and palliation of symptoms, 
maintenance or improvement of quality of life and pro-
longation of survival. In the palliative setting, there is 
currently no standard care for this heterogeneous group 
of patients  [3, 5, 6] . Treatment decisions are made on an 
individual basis, and the decision-making process re-
garding which agents to select from the wide array of an-
tineoplastic drugs available is complex. The choice of the 
therapy regimen depends on a large number of consider-
ations  [2, 3] :
 – Patient-related factors: age, presence of comorbidities, 
physical condition, personal preferences and motiva-
tion 
 – Prognostic factors: interval from initial diagnosis to 
diagnosis of metastatic disease, rate of disease pro-
gression, number and site of metastases 
 – Biologic factors: hormone receptor and HER-2/neu 
status  
 – Case-related factors: type of adjuvant therapy re-
ceived 
 – Symptom-related factors: need for rapid alleviation of 
severe disease-related symptoms  
 – Therapy-related factors: expected efficacy, type and 
extent of side effects, complications of prior therapy 
 – Physician-related factors: estimates of prognosis, ex-
perience, personal preferences towards certain agents, 
ability to communicate and involve the patient and her 
family  
 – Socioeconomic factors: insurance status, availability 
of certain agents (these factors did not play a role in 
our study cohort in Switzerland) 
 In the literature, there is a large amount of evidence-
based information concerning possible therapy options. 
However, most of the published studies evaluate only cer-
tain therapy options in preselected groups of patients in 
selected situations and do not describe the overall course 
of metastatic disease. Decision algorithms to assist physi-
cians in choosing appropriate therapies have been estab-
lished  [3] . To the best of our knowledge, our study is the 
first to evaluate from a population-based perspective 
over a fairly long period of time (1990–2006) how the 
available therapy options and regimens are implemented 
in clinical practice. Although the database from which 
our data were derived was created from a single primary 
treatment unit, the results of our study reflect the gen-
eral palliative therapy situation. During the follow-up of 
our patients, information concerning palliative treat-
ment was obtained from approximately 20 oncology units 
in Switzerland, as well as neighboring regions in Germa-
ny and France.
 Since there has been considerable change in the last 2 
decades in the number and type of agents available, we 
divided the patients of our study group into two sub-
groups according to the date of initial diagnosis of meta-
static disease. As demonstrated in  table 5 , therapy regi-
mens and certain drugs were used in the earlier group 
from 1990 to 1997 (e.g., endocrine therapy: aminoglu-
tethimide, megestrol acetate, medroxyprogesterone ace-
tate; chemotherapy: Leukeran, methotrexate, mitomy -
cin C, mitoxantrone, cyclophosphamide, fluorouracil), 
which have mostly been replaced by modern agents and 
concepts. The second cohort, which consists of patients 
whose palliative treatment started after 1998, reflects the 
contemporary treatment situation with currently used 
agents (e.g., endocrine therapy: third-generation aroma-
tase inhibitors, fulvestrant; chemotherapy: taxanes, cape-
citabine, liposomal doxorubicin, gemcitabine, vinorel-
bine; trastuzumab).
 It was the goal of this study to depict the entire group 
of patients with metastatic disease in a population-based 
manner. In order to best achieve this, patients who re-
ceived no treatment by specialized oncologists also had 
to be included. The number of patients who died from 
metastatic disease without receiving any antineoplastic 
therapy was surprisingly high: altogether 13.2%. The lack 
of treatment was most commonly seen in the subgroup of 
older patients, since the physical condition and frequent 
comorbidities of these patients make oncologic therapies 
often impossible. However, in the subgroup of patients 
who were younger than 60 years, approximately 10% also 
did not receive any therapy before a breast cancer-related 
death occurred. This group of younger women rarely had 
any relevant comorbidities and were potential candidates 
for chemotherapy. This finding can be explained, exclud-
ing the few patients who had a fulminant disease course 
and thus could not begin timely therapy, by the fact that 
most patients in this group were individuals who know-
ingly declined therapy. Such patients are rarely ever even 
seen by a specialized oncologist and thus play little role 
in their perception of the disease. Despite the undisputed 
success of modern therapy approaches, a certain percent-
age of the population may have a profound mistrust of 
and aversion to modern western medicine and declines 
such treatment. Skepticism of more aggressive therapy 
regimens is also reflected in the fact that in the group of 
patients who died of cancer and received treatment, ap-
proximately 25% only had endocrine regimens, and of 
these patients, approximately 20% were younger than 60 
years.
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 In recent years, older breast cancer patients have come 
increasingly into the focus of interest. Today, women old-
er than 70 years treated with chemotherapy for meta-
static disease derive similar benefits as their younger 
counterparts  [7] . In the last decade, chemotherapy in the 
palliative situation has changed in such a way that even 
older women can receive these therapy regimens. Cur-
rently, there is a selection of drugs with safer profiles, in-
cluding weekly taxane regimens, newer less cardiotoxic 
anthracycline formulations, capecitabine, gemcitabine, 
and vinorelbine. In addition to new antineoplastic drugs, 
some advances have been made in supportive care. In our 
study, patients older than 70 years who qualified for che-
motherapy received on average two lines of treatment, 
which was equal to the median number of lines adminis-
tered in younger patient groups  [8] . These results confirm 
the feasibility of chemotherapy in older patients. Surpris-
ingly, the general readiness for treatment with chemo-
therapy, probably of both the physicians and patients, did 
not change over time. In our study, the number of pa-
tients who were older than 70 years and received chemo-
therapy in the current study period (1998–2006) did not 
significantly differ from that in the preceding 10-year ob-
servation period (although the agents prescribed had 
changed).
 Our study confirms the findings and conclusions of 
Andre et al.  [9] and Chia et al.  [8] who found that an im-
proved survival was associated with the use of newer 
agents and regimens over time. This finding is even more 
relevant when one considers that an increased use of ad-
juvant therapy in the later cohorts may have reduced the 
effectiveness of subsequent palliative systemic therapy in 
these patients, since a greater proportion was no longer 
‘therapy naive’; in this context, it should be mentioned 
that the increased use of adjuvant therapies, both chemo- 
and endocrine therapies, may explain the differences in 
the median disease-free survival (group A: 44.5 months; 
group B: 25.5 months). We agree with Chia et al. that lead-
time bias, such as improved diagnostic testing and change 
of the follow-up guidelines, did not contribute signifi-
cantly to this development. Furthermore, we agree with 
them that improved survival cannot be attributed to a 
single agent or regimen. The differences in survival are 
most likely associated with the introduction of a new gen-
eration of agents, above all the third-generation aroma-
tase inhibitors letrozole, anastrozole and exemestane 
(these agents made up 65% of the endocrine therapies of 
patients whose metastases were diagnosed after 1998, 
while in the preceding period it was only 15%), new che-
motherapy agents and trastuzumab (taxanes, liposomal 
doxorubicin, vinorelbine, gemcitabine, capecitabine and 
trastuzumab made up approximately 80% of therapies in 
patients whose metastases were diagnosed after 1998, 
while in the preceding period it was only 13%). The fact 
that there were no significant differences in either the 
mean or the median number of treatments delivered be-
tween the two cohorts underlines our conclusion that the 
use of newer agents and regimens improved survival.
 Despite the progress made in palliative therapy, one 
should remain aware of the fact that the majority of pa-
tients have only a limited survival time of 18–24 months 
after the initial diagnosis of distant metastases  [8, 10, 11] . 
In this short time period, only a limited number of ther-
apy lines can be administered. Evidence-based medicine 
provides some support for the use of second-line and, to 
a lesser degree and in selected cases, third-line chemo-
therapy; beyond third-line treatment, there are no data 
that suggest a clear potential benefit for such a therapeu-
Table 5. Chemotherapies, trastuzumab and endocrine therapies 
administered for the treatment of metastatic breast cancer
Group A Group B
Chemotherapy/trastuzumab, %
Conventional anthracyclines 6.7 19.9
Liposomal doxorubicin 9.3 0.8
Paclitaxel 9.3 2.7
Docetaxel 6.5 1.2
Vinorelbine 16.8 4.3
Gemcitabine 8.8 0.4
Capecitabine 15.5 2.7
Trastuzumab 13.2 0.8
Cyclophosphamide 4.9 13.7
Methotrexate 1.5 15.3
5-Fluorouracil 1.5 17.2
Mitomycin C 0.8 5.2
Leukeran 0.3 5.2
Novantron 2.1 7.8
Others 2.8 2.8
Endocrine therapy, %
Tamoxifen 20.8 40.7
Megestrol acetate 4.1 20.4
Aminoglutethimide – 21.2
Third-generation aromatase inhibitor 64.9 15.0
Luteinizing hormone-releasing
hormone agonists 4.1 2.7
Fulvestrant 6.1 –
Analyses also included patients with ongoing therapies. Group 
A = Distant metastases first diagnosed in 1998–2006, n = 106; 
group B = distant metastases first diagnosed in 1990–1997, n = 
191.
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tic approach  [12] . In our current study cohort, 75% of the 
patients who received chemotherapy did not receive more 
than three lines of treatment.
 In conclusion, we believe that this is the first study to 
give a population-based image of the palliative treatment 
situation in metastatic breast cancer and to demonstrate 
to what extent therapy decision algorithms were imple-
mented in the clinical practice. Although metastatic 
breast cancer still has to be considered as an incurable 
disease, we support the hope that through the availabil-
ity and use of newer and more effective systemic agents, 
the outcome of patients can be improved. This trend pro-
vides hope for further improvement in the treatment of 
metastatic disease in the future.
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